Related Experiment Video

Updated: Jul 17, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Tumor necrosis factor blockade in the management of children with orphan diseases

Riva Brik1, Vardit Gepstein, Eli Shahar

  • 1Department of Pediatrics, Meyer Children's Hospital of Haifa, P.O. Box 9602, Technion, Haifa 31096, Israel. r_brik@rambam.health.gov.il

Clinical Rheumatology
|January 16, 2007
PubMed

Insights

Tumor necrosis factor (TNF) blockade shows promise for rare childhood vasculitis. Infliximab, an anti-TNF antibody, was explored in three children with these conditions.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Systemic Inflammatory Diseases

Background:

  • Tumor necrosis factor (TNF) blockade is established for rheumatic disorders like juvenile idiopathic arthritis (JIA).
  • TNF antagonists are being investigated for rare systemic inflammatory diseases.
  • Preliminary adult data suggest efficacy in various vasculitides.

Observation:

  • This study details limited experience with infliximab in three children.
  • The children had rare systemic vasculitic conditions.
  • Infliximab is a chimeric monoclonal anti-TNF antibody.

Findings:

  • Infliximab demonstrated potential in treating these rare pediatric vasculitis cases.
  • The response to infliximab was observed in the treated children.
  • This suggests a possible therapeutic role for infliximab in pediatric vasculitis.

Implications:

  • Infliximab may be a viable treatment option for children with specific rare vasculitides.
  • Further research is warranted to confirm the efficacy and safety of TNF blockade in pediatric vasculitis.
  • This approach could offer new therapeutic avenues for severe pediatric inflammatory conditions.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...